Pharmacy industry leader joins Biosign team



    Phil Rosenberg, new VP Marketing, to play key role in commercialization
    of UFIT(R) health monitor

    TORONTO, June 11 /CNW/ - Biosign Technologies Inc. (CNQ: BIOS), a medical
technology company, announced that Phil Rosenberg, a veteran leader in
Canada's pharmaceutical industry, has joined the company. In the newly-created
position of Vice President, Marketing, Mr. Rosenberg will play a central role
in the commercialization of Biosign's UFIT(R) health monitoring system.
    Mr. Rosenberg will use his extensive experience, industry knowledge and
contacts to build awareness of UFIT(R)'s capabilities for measuring blood
pressure, blood glucose and other patient vital signs, and work with other
organizations to market and sell the system.
    "Mr. Rosenberg's appointment signals a new phase for Biosign as we move
from research and development to commercialization," said Richard Potts,
Chairman and CEO, Biosign. "With more than 25 years of experience in the
pharmacy business, he brings expertise and relationships that are enormous
assets in taking UFIT(R) to market."
    Before joining the company, Mr. Rosenberg provided consulting services to
Biosign and businesses in the pharmacy supply chain industry. Prior to that,
he was President and CEO of the Canadian Association for Pharmacy Distribution
Management, a leading health care industry association with a unique focus on
supply chain management. His understanding of the pharmaceutical industry
spans the pharmacy business, manufacturing and government relations.
    A professional pharmacist, Mr. Rosenberg worked for many years as an
executive at several leading pharmacy retail chains, and he was a founding
member of the Canadian Association of Chain Drug Stores, where he served in an
executive role.
    Mr. Rosenberg has been a speaker at numerous seminars in both the drug
and natural health care fields, and has written many articles on these
subjects.

    About Biosign Technologies Inc.

    Biosign develops technologies, products and initiatives to address
critical problems in global health care. The focus is on measuring health
status, outcomes, and risk toward maximizing clinical awareness, readiness,
and effectiveness. The thrust is on enabling autonomous medical care in a way
that optimizes quality, access, and cost. The core technology expands virtual
instrumentation by adding universal measurement and rapid knowledge formation
to support service oriented enterprising across global markets. Trademarked
UFIT, the web-based technology powers several business lines in adaptive
clinical trials, self-care, medical homes, distributed diagnostics and home
health care. Regulated applications of UFIT(R) include intelligent systems for
noninvasive monitoring at the point of care which are useful in optimizing
health and managing chronic diseases such as hypertension and diabetes.

    -------------------------------------------------------------------------

    Forward-Looking Statements

    This press release contains forward looking statements. Forward looking
    statements are not based on historical facts, but rather on current
    expectations, Company assumptions and projections about future events,
    and are therefore subject to risks and uncertainties which could cause
    actual results to differ materially from the future results expressed or
    implied by the forward looking statements. Such statements are qualified
    in their entirety by the inherent risks and uncertainties surrounding
    future expectations. Company assumptions and risk factors are listed from
    time to time in Biosign's reports, public disclosure documents including
    Management's Discussion and Analysis, Management Information Circular,
    and in other filings with stock exchanges and securities regulatory
    authorities in Canada.

    You should not place undue importance on forward-looking statements and
    should not rely upon this information as of any other date. While Biosign
    may elect to, Biosign is under no obligation and does not undertake to
    update this information at any particular time. This press release was
    prepared by management from information available to the date of this
    release.

    -------------------------------------------------------------------------
    %SEDAR: 00014068E




For further information:

For further information: Richard Potts, Chairman & CEO, Phone: (416)
218-9800 ext. 234, Email: richardp@biosign.com; Media inquiries, Don Hogarth,
Hogarth Communications, Phone: (416) 565-8920, don@hogarthpr.com

Organization Profile

Biosign Technologies Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890